Understanding responses to contradictory information about products

Marketing Science

Volumn 30, Issue 6, 2011, Pages 1098-1114

  Kalra, Ajay ^a   Li, Shibo ^b   Zhang, Wei ^c  

^a RICE UNIVERSITY   (United States)

^b INDIANA UNIVERSITY   (United States)

^c IOWA STATE UNIVERSITY   (United States)

Author keywords

Contradictory information; Endogeneity; Hierarchical bayes models; Learning models; Pharmaceutical markets

Indexed keywords

EID: 83455179629     PISSN: 07322399     EISSN: 1526548X     Source Type: Journal    
DOI: 10.1287/mksc.1110.0671     Document Type: Article

References (32)

1. Ahluwalia, R. 2002. How prevalent is the negativity effect in consumer environments? J. Consumer Res. 29(2) 270-279.
2. Ahluwalia, R., R. E. Burnkrant, H. R. Unnava. 2000. Consumer response to negative publicity: The moderating role of commitment. J. Marketing Res. 37(2) 203-214.
3. American Diabetes Association. 2007. Statement from the American College of Cardiology, American Diabetes Association and American Heart Association related to NEJM article, Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. Press release (May 21), http:// www.diabetes.org/for-media/2007/statement-from-the-aha-acc -ada-nejm-article-2007.html.
4. Bandura, A. 1982. Self-efficacy mechanism in human agency. Amer. Psych. 37(2) 122-147.
5. Chan, T., C. Narasimhan, Y. Xie. 2010. An empirical model of physician learning on treatment effectiveness and side-effects. Working paper, Washington University in St. Louis, St. Louis.
6. Chib, S., E. Greenberg. 1995. Understanding the Metropolis- Hastings algorithm. Amer. Statistician 49(4) 327-335.
7. Ching, A. T. 2010. Consumer learning and heterogeneity: Dynamics of demand for prescription drugs after patent expiration. Internat. J. Indust. Organ. 28(6) 619-638.
8. Chintagunta, P. K., R. Jiang, G. Z. Jin. 2009. Information, learning and drug diffusion: The case of Cox-2 inhibitors. Quant. Marketing Econom. 7(4) 399-433.
9. Cleeren, K., M. G. Dekimpe, K. Helsen. 2008. Weathering productharm crises. J. Acad. Marketing Sci. 36(2) 262-270.
10. CTC. Helmets. Accessed February 2009, http://www.ctc.org.uk/ resources/Campaigns/Helmets.pdf.
11. Dawar, N., M. M. Pillutla. 2000. Impact of product-harm crises on brand equity: The moderating role of consumer expectations. J. Marketing Res. 37(2) 215-226.
12. Dong, X., P. Manchanda, P. K. Chintagunta. 2009. Quantifying the benefits of individual-level targeting in the presence of firm strategic behavior. J. Marketing Res. 46(2) 207-221.
13. Erdem, T., M. P. Keane. 1996. Decision-making under uncertainty: Capturing dynamic brand choice process in turbulent consumer goods markets. Marketing Sci. 15(1) 1-20.
14. European Medicines Agency. 2007. European Medicines Agency confirms positive benefit-risk balance for rosiglitazone and pioglitazone. Press release (October 18), http://www.emea.europa.eu/docs/en_GB/document_library/Press_release/2009/ 11/WC5000011009.pdf.
15. Gelfand, A. E., A. F. M. Smith. 1990. Sampling-based approaches to calculating marginal densities. J. Amer. Statist. Assoc. 85(410) 398-409.
16. Gist, M. E., T. R. Mitchell. 1992. Self-efficacy: A theoretical analysis of its determinants and malleability. Acad. Management Rev. 17(2) 183-211.
17. Hoff, T. H., W. F. Whitcomb, K. Williams, J. R. Nelson, R. A. Cheesman. 2001. Characteristics and work experiences of hospitalists in the United States. Arch. Internal Medicine 161(6) 851-858.
18. Manchanda, P., A. Ansari, S. Gupta. 1999. The "shopping basket": A model for multi-category purchase incidence decisions. Marketing Sci. 18(2) 95-114.
19. Manchanda, P., P. Rossi, P. Chintagunta. 2004. Response modeling with nonrandom marketing-mix variables. J. Marketing Res. 41(4) 467-478.
20. McGuire, S. 2007. FDA toughens Avandia warnings. Medical Marketing & Media (November 14) http://www.mmm-online.com/fda-toughens-avandia-warnings/article/96354.
21. Mehta, N., X. Chen, O. Narasimhan. 2008. Informing, transforming, and persuading: Disentangling the multiple effects of advertising on brand choice decisions. Marketing Sci. 27(3) 334-355.
22. Narayanan, S., P. Manchanda. 2009. Heterogeneous learning and the targeting of marketing communication for new products. Marketing Sci. 28(3) 424-441.
23. Narayanan, S., P. Manchanda, P. K. Chintagunta. 2005. Temporal differences in the role of marketing communication in new product categories. J. Marketing Res. 42(3) 278-290.
24. Nissen, S., K. Wolski. 2007. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. New Engl. J. Medicine 356(24) 2457-2471.
25. Psaty, B. M., C. D. Furberg. 2007. Editorials: Rosiglitazone and cardiovascular risk. New Engl. J. Medicine 356(24) 2522-2524.
26. Rodgers, G. B. 1988. Reducing bicycle accidents: A re-evaluation of the impacts of the CPSC bicycle standard and helmet use. J. Products Liability 11(11) 307-317.
27. Rossi, P. E., R. E. McCulloch, G. M. Allenby. 1996. The value of purchase history data in target marketing. Marketing Sci. 15(4) 321-340.
28. Sun, B., S. Li. 2011. Learning and acting on customer information: A simulation-based demonstration on service allocations with offshore centers. J. Marketing Res. 48(1) 72-86.
29. Tanner, M. A. W. H. Wong. 1987. The calculation of posterior distributions by data augmentation. J. Amer. Statist. Assoc. 82(398) 528-540.
30. Thompson, R. S., F. P. Rivara, D. C. Thompson. 1989. A case control study of the effectiveness of bicycle safety helmets. New Engl. J. Medicine 320(21) 1361-1367.
31. U.S. House of Representatives. 2007. FDA's role in the evaluation of Avandia's safety. Prepared statement of Brian L. Storm. Hearing, Committee on Oversight and Government Reform, 110th Cong., 1st sess., June 7.
32. Van Heerde, H., K. Helsen, M. G. Dekimpe. 2007. The impact of a product-harm crisis on marketing. Marketing Sci. 26(2) 230-245.